8-K: Adagio Medical Completes Merger with ARYA IV, Begins Trading on Nasdaq

Adagio Medical Holdings, Inc. begins trading on the Nasdaq after completing its business combination with ARYA IV, focusing on innovative cardiac arrhythmia treatment technologies.

Summary

• Adagio Medical Holdings, Inc. has completed its business combination with ARYA Sciences Acquisition Corp IV.
• The combined company will trade on the Nasdaq under the ticker symbol ADGM starting August 1, 2024.
• Adagio Medical will operate as a subsidiary of Adagio Medical Holdings, Inc.
• The transaction included approximately $84.2 million in financing, consisting of funds from ARYA IV's trust account, a private placement, and a convertible security financing.
• The private placement was led by affiliates of Perceptive Advisors, RA Capital Management, and RTW Investments.
• The convertible security financing was led by an institutional investor and an affiliate of Perceptive Advisors.
• Adagio Medical has developed ultra-low temperature cryoablation (ULTC) and pulsed-field cryoablation (PFCA) technologies for treating cardiac arrhythmias.
• The company has received CE Marking in Europe for its iCLAS and VT ULTC systems and is seeking regulatory approval in the U.S.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The successful merger and financing are positive, but the company's financial situation and the risks associated with the business are concerning. The sentiment is cautiously optimistic.

Positives

• The business combination provides Adagio Medical with significant capital to advance its commercialization and clinical trial efforts.
• The company has a robust pipeline of innovative ablation technologies.
• Adagio Medical has already achieved regulatory approvals in Europe for some of its products.
• The company has promising clinical data from its CRYOSURE-2 and CRYOCURE-VT trials.

Negatives

• Adagio Medical has incurred net losses in each quarterly and annual period since inception and has not yet generated any meaningful revenue.
• Adagio Medicals management does not believe its current cash and cash equivalents are sufficient to fund operations for at least the next 12 months from the issuance date of the financial statements, which Adagios management believes raises substantial doubt about Adagios ability to continue as a going concern.

Risks

• The company faces risks related to competition, regulatory approvals, and the ability to manage growth profitably.
• Adagio Medicals ability to remain compliant with the covenants of its existing debt, including any convertible or bridge financing notes.
• New Adagios ability to remain compliant with the covenants of, and other obligations under, the senior secured convertible notes that were issued in connection with the closing of the Business Combination.
• The company may be adversely affected by economic, business, and/or competitive factors.
• The company may not be able to achieve its expected pro forma cash, cash runway or funding gap, estimates of expenses and profitability.

Future Outlook

The company expects to incur increasing costs as it continues to devote substantially all of its resources towards the development and anticipated further commercialization of its products, including iCLAS, vCLAS and Cryopulse. Adagios management does not believe its current cash and cash equivalents are sufficient to fund operations for at least the next 12 months from the issuance date of the financial statements, which Adagios management believes raises substantial doubt about Adagios ability to continue as a going concern.

Management Comments

• Olav Bergheim, Chief Executive Officer of Adagio Medical and Adagio Medical Holdings, Inc., stated that the transaction starts a new chapter in the companys journey and that their principal focus will be on commercialization of the vCLAS ultra-low temperature cryoablation (ULTC) catheter for treatment of ventricular tachycardia (VT) and on the execution of the FULCRUM-VT Pivotal IDE trial.
• Adam Stone, Chief Investment Officer of Perceptive Advisors and CEO of ARYA IV, stated that they are excited to partner with Adagio Medical to support the development of its innovative ablation technologies for the treatment of ventricular tachycardia and other cardiac arrhythmias and that they believe that their ability to create deep and durable cardiac lesions is poised to result in enhanced effectiveness and outcomes.

Industry Context

This announcement reflects a trend of medical device companies seeking public market access through mergers with special purpose acquisition companies (SPACs). The focus on innovative ablation technologies for cardiac arrhythmias aligns with the growing market for advanced electrophysiology devices.

Comparison to Industry Standards

• The document mentions that Adagio's CRYOSURE-2 trial showed 85% freedom from AF after a single ULTC procedure, compared to 51%-65% reported for other catheter technologies.
• The CRYOCURE-VT trial showed a 0% rate of major adverse events in VT patients, compared to 11.5% reported for other VT ablation procedures.
• The document does not provide specific comparisons to other companies, but it highlights the favorable outcomes of Adagio's technology compared to existing standards of care.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions that there are risks and uncertainties described in the Proxy Statement/Prospectus relating to the Business Combination, which has been filed by ListCo with the SEC, and described in other documents filed by ARYA or New Adagio from time to time with the SEC.
• The document also mentions the outcome of any potential litigation, government or regulatory proceedings that may be instituted against Adagio, New Adagio or others as a risk factor.

Related Party Transactions

• The document mentions that the ARYA Sponsor received 499,000 shares of New Adagio Common Stock in exchange for the private placement Class A ordinary shares held by it.
• The document also mentions that shares of New Adagio Common Stock were issued to the Sponsor in connection with the Sponsors option to contribute the ARYA Convertible Promissory Notes to ARYA in exchange for Class A ordinary shares.

Stakeholder Impact

• Shareholders of ARYA IV have the opportunity to participate in the growth of a medical device company focused on innovative technologies.
• Employees of Adagio Medical will become part of a publicly traded company with access to new resources and opportunities.
• Customers of Adagio Medical will benefit from the continued development and commercialization of its products.
• Suppliers and creditors of Adagio Medical will be impacted by the financial changes resulting from the merger.

Next Steps

• The company will focus on commercialization of the vCLAS ultra-low temperature cryoablation (ULTC) catheter for treatment of ventricular tachycardia (VT) in Europe.
• The company will execute the FULCRUM-VT Pivotal IDE trial in the U.S.
• The company will seek regulatory approvals in the U.S. for its iCLAS and VT ULTC systems.
• The company will seek approval for the PFCA system after completion of the PARALELL trial.

Key Dates

Keywords

Adagio Medical, ARYA IV, business combination, Nasdaq, cardiac arrhythmias, ablation, cryoablation, ventricular tachycardia, atrial fibrillation, medical device, Perceptive Advisors, PIPE financing, convertible notes